779 patents
Page 14 of 39
Utility
Chimeric Antigen Receptors Targeting Epidermal Growth Factor Receptor Variant III
21 Jul 22
The invention provides Chimeric Antigen Receptors (CARs) that specifically bind to EGFRvIII (Epidermal Growth Factor Receptor Variant III).
Oi Kwan Wong, Joyce Ching Chou, Mathilde Brunnhilde Dusseaux, Julianne Smith, Barbra Johnson Sasu
Filed: 27 Jan 22
Utility
Protease-activating CD45-GATE Car
21 Jul 22
A reversibly gated effector polypeptide e.g. a chimeric antigen receptor (protease-activating CD45-gate CAR) comprising an extracellular CD45 recruiting domain, a protease-cleavable linker, and a polypeptide comprising an extracellular ligand binding domain, a transmembrane domain, and an intracellular domain.
Shanshan LANG, Thomas John VAN BLARCOM, Michael Thomas BETHUNE, Siler PANOWSKI, Nguyen TAN, Yi ZHANG, Barbra Johnson SASU, Zhe LI
Filed: 21 Dec 21
Utility
6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands
19 Jul 22
Thomas Allen Chappie, Jaclyn Louise Henderson, Joseph Michael Young, Travis T. Wager, Bethany Lyn Kormos, Nandini Chaturbhai Patel, Simone Sciabola, Jamison Bryce Tuttle, Patrick Robert Verhoest, Joseph Walter Tucker
Filed: 23 Jan 20
Utility
Dosing Regimen of Avelumab for the Treatment of Cancer
14 Jul 22
The present invention relates to dosing regimen of avelumab for the treatment of cancer.
Glen Ian Andrews, Carlo Leonel BELLO, Satjit Singh BRAR, Shaonan WANG, Pascal GIRARD
Filed: 9 Feb 22
Utility
Pharmaceutical combinations
5 Jul 22
Provided herein are pharmaceutical combinations comprising (a) a B-Raf inhibitor, or a pharmaceutically acceptable salt thereof, (b) at least one mitogen activated protein kinase (MEK) inhibitor, or a pharmaceutically acceptable salt thereof, and (c) an epidermal growth factor receptor (EGFR) inhibitor or a pharmaceutically acceptable salt thereof; and optionally at least one pharmaceutically acceptable carrier; methods for preparing the pharmaceutical combinations, and the uses of the pharmaceutical combinations in the treatment of proliferative diseases, such as cancer.
Giordano Caponigro, Zhu Alexander Cao
Filed: 24 Sep 19
Utility
Method for controlling
5 Jul 22
The present invention provides improved methods for producing a solution containing high molecular weight isolated Streptococcus pneumoniae capsular polysaccharides having phosphodiester linkages between saccharide repeat units.
Jean Heather Crinean
Filed: 25 Jun 20
Utility
Antibodies specific for CD70 and their uses
5 Jul 22
The present invention provides antibodies that specifically bind to CD70 (Cluster of Differentiation 70).
Siler Panowski, Tao Sai, Barbra Johnson Sasu, Surabhi Srivatsa Srinivasan, Thomas John Van Blarcom
Filed: 31 Jan 19
Utility
Real-time Tracking and Management of Standard Workflows
30 Jun 22
Lean manufacturing principles are integrated into computing components for the generation, collection, analysis, and propagation of real-time manufacturing and supply operations data.
Michael P. CAREY, Matthew Brian ELK, Maxwell Noah GOTT, René LEHOUX, Kailin Haley MACINTYRE, David Scott MCGETTIGAN, John Paul MCTERNAN, Jefferey Maurice MOORE, Cian O'MEARA, Sara Tali OPPENHEIMER, Michael Henry TOMASCO, Yiming XIAO
Filed: 30 Apr 20
Utility
E. Coli Fimh Mutants and Uses Thereof
30 Jun 22
This disclosure relates to the design of E. coli mutated FimH polypeptides that result in improved biochemical properties and immunogenicity, compositions comprising such polypeptides, and uses thereof.
Ye Che, Laurent Oliver Chorro, Robert George Konrad Donald, Matthew Curtis Griffor, Natalie Clare Silmon de Monerri
Filed: 17 Dec 21
Utility
Metabolites of GLP1R Agonists
23 Jun 22
The present invention provides metabolites of Compound 1 or a compound of Formula I or III, including compositions and salts thereof, which are useful in the prevention and/or treatment of a disease or disorder such as T2DM, obesity, or NASH, as well as analytical methods related to the administration of Compound 1 or a compound of Formula I or III.
Andrew John Bessire, David James Edmonds, David Andrew Griffith, Amit Sumant Kalgutkar
Filed: 9 Dec 21
Utility
Cysteine engineered antibody drug conjugates
21 Jun 22
The invention relates to polypeptides, antibodies, and antigen-binding fragments thereof, that comprise an engineered cysteine for site-specific conjugation.
Madan Katragadda, Russell Dushin, Lawrence Nathan Tumey
Filed: 24 Sep 18
Utility
Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
21 Jun 22
Bing Wang, Daniel Chu
Filed: 21 Aug 20
Utility
Anti-ROBO2 antibodies, compositions, methods and uses thereof
21 Jun 22
The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to ROBO2, as well as uses, and methods thereof.
Stephen Berasi, Janet Elizabeth Buhlmann, Eric M. Bennett, Nathan Higginson-Scott, Huilan Gao, Zong Sean Juo, Stefano V. Gulla, Christine Huard, Sreekumar R. Kodangattil, Jian Li, Weining Lu, Xueping Fan, David J. Salant
Filed: 8 Jun 18
Utility
Bifunctional cytotoxic agents containing the CTI pharmacophore
21 Jun 22
Andreas Maderna, Chakrapani Subramanyam, Lawrence N. Tumey, Zecheng Chen, Jeffrey M. Casavant
Filed: 6 Nov 20
Utility
(AZA)Benzothiazolyl Substituted Pyrazole Compounds
16 Jun 22
Shawn Cabral, Daniel Paul Canterbury, Robert Lee Dow, Andrew Fensome, Magdalena Korczynska, Sophie Yvette Lavergne, Allyn Timothy Londregan, Vincent Mascitti, David Walter Piotrowski, Andre Shavnya, Meihua Mike Tu, Tao Wang, Hanna Maria Wisniewska
Filed: 23 Nov 21
Utility
Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens, Kits Comprising the Same and Uses Thereof
16 Jun 22
The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof.
Annaliesa Sybil Anderson, Isis Kanevsky, Farid Latif Khan, Charles Harold Jones, John Michael McLaughlin
Filed: 6 Apr 20
Utility
Anti-AVB8 antibodies and compositions and uses thereof
14 Jun 22
The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to αvβ8 integrin.
Kyle Steven Niessen, Dharmaraj Samuel, Charles Ray Holst, Matthew Ross Drever, Dean Sheppard, Rosemary J. Akhurst, Amha Atakilit, Dominique Meyer, Isaac J. Rondon, Joseph Dal Porto
Filed: 5 Sep 19
Utility
Stable Liquid Antibody Formulation
9 Jun 22
The present invention relates generally to the field of pharmaceutical formulations of antibodies.
Advait Vijay Badkar, Leigh Kristen Bohack, Kevin Roger King, Alanta Lea Lary
Filed: 16 Jul 21
Utility
Nitrile-containing antiviral compounds
7 Jun 22
Dafydd Rhys Owen, Martin Youngjin Pettersson, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Patrick Robert Verhoest, Liuqing Wei, Qingyi Yang, Xiaojing Yang
Filed: 5 Aug 21
Utility
PHOSPHATIDYLINOSITOL-3-KINASE Pathway Biomarkers
2 Jun 22
Methods for treating breast cancer, specifically cancers resistant to treatment With one or more known breast cancer treatment drugs, and related patient selection strategies for predicting patient response to drug therapy, such strategies including detecting tile presence or absence in a patient of one or more of PIK3CA gene amplification a mutation in PIK3CA, and a decrease in PTEN protein expression, and treating a patient positive for the presence of one or more of same by administering to the subject a pan-ErbB tifrosine kinase inhibitor.
Anna Berkenblit, Christina Marie Coughlin, Jay Marshall Feingold, Daniel Stephen Johnston, Andrew Louis Strahs, Charles Michael Zacharchuk
Filed: 9 Nov 21